Skip to main content

News Room

FDA AWARDS BREAKTHROUGH DEVICE STATUS TO THE DPP® SYPHILIS TnT ASSAY

| Uncategorized | No Comments
FOOD AND DRUG ADMINISTRATION AWARDS BREAKTHROUGH DEVICE STATUS TO THE DPP® SYPHILIS TnT ASSAY  Medford, N.Y. USA / Strasbourg, France – July 29, 2025 – Chembio Diagnostic Systems, Inc., a…

FDA Awards Breakthrough Device Status to the SURE CHECK® HIV Self-Test

| Chembio | No Comments
Medford N.Y USA/Strasbourg France – June 17, 2025 – Chembio Diagnostic Systems, Inc., a subsidiary of Biosynex, developer and manufacturer of rapid diagnostic tests, announced today that the U.S. Food…

Chembio Diagnostics Inc. receives a grant for Development of a DPP Congenital Syphilis Assay

| Chembio | No Comments
Chembio Diagnostics Inc., a subsidiary of Biosynex, receives a grant  for Development of a DPP Congenital Syphilis Assay Medford N.Y USA/Strasbourg France , Oct 23, 2024   Chembio Diagnostics, Inc. (Chembio), a…
Bio Synex Logo

Biosynex Completes Acquisition of Chembio Diagnostics, Inc.

| Chembio | No Comments
Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market…

Subscribe to the Chembio Mailing List